retatrutide trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Eli Lilly's Retatrutide Phase 3
Description
Diabetes impairs Wnt3 protein-induced neurogenesis in olfactory bulbs via glutamate transporter 1 inhibition
& Allen, N

Psychiatry Investigation, 11 (2), 167172

If you place the unopened vial in a standard refrigerator (around 2C to 8C or 36F to 46F), it can remain stable for many months, often up to a year or more
A new study using fitness tracker data reveals that older adults taking GLP-1 weight loss medications are exercising less, which could lead to unintended consequences, like overall weakness
